Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.
Reinhard Dummer(University Hospital of Zurich), Georgina V. Long(The University of Sydney), Célèste Lebbé(Inserm), Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ronnie Shapira‐Frommer(Sheba Medical Center), Jean‐Jacques Grob(Aix-Marseille Université), Andrew Hill(University of Auckland), Xuan Peng(Cancer Research And Biostatistics), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stéphane Dalle(Hospices Civils de Lyon), Jonathan Cohen(King's College London), Caroline Robert(Institut Gustave Roussy), Rohini Singh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anna Maria Di Giacomo(University of Siena), Sekwon Jang(Virginia Cancer Institute), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Muhammad Adnan Khattak(Edith Cowan University), Giuseppe Curigliano(European Institute of Oncology)
Cited by 4
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k